Overview Dividends

(ABSI) Absci - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00091E1091

Therapeutic Antibodies, Inflammatory Treatments, Oncology Drugs

ABSI EPS (Earnings per Share)

EPS (Earnings per Share) of ABSI over the last years for every Quarter: "2020-09-30": null, "2020-12-31": -0.7042, "2021-03-31": -0.1784, "2021-06-30": -2.39, "2021-09-30": -0.33, "2021-12-31": -0.28, "2022-03-31": -0.33, "2022-06-30": -0.32, "2022-09-30": -0.3, "2022-12-31": -0.21, "2023-03-31": -0.26, "2023-06-30": -0.45, "2023-09-30": -0.24, "2023-12-31": -0.25, "2024-03-31": -0.22, "2024-06-30": -0.22, "2024-09-30": -0.2412, "2024-12-31": -0.25, "2025-03-31": -0.21, "2025-06-30": -0.24,
EPS Growth (3Y CAGR): 11.37%
EPS Trend (3Y Correlation): 36.1%

ABSI Revenue

Revenue of ABSI over the last years for every Quarter: 2020-09-30: 0.916, 2020-12-31: 2.728, 2021-03-31: 1.063, 2021-06-30: 0.728, 2021-09-30: 1.539, 2021-12-31: 1.452, 2022-03-31: 0.819, 2022-06-30: 1.002, 2022-09-30: 2.369, 2022-12-31: 1.557, 2023-03-31: 1.269, 2023-06-30: 3.367, 2023-09-30: 0.744, 2023-12-31: 0.338, 2024-03-31: 0.898, 2024-06-30: 1.27, 2024-09-30: 1.701, 2024-12-31: 0.665, 2025-03-31: 1.179, 2025-06-30: 0.593,
Revenue Growth (3Y CAGR): -39.57%
Revenue Trend (3Y Correlation): -45.9%

Description: ABSI Absci

Absci Corporation is a biotechnology company leveraging generative AI to create novel antibody therapeutics. By integrating AI-driven design with wet lab technologies, the company aims to develop differentiated treatments for various diseases, including inflammatory bowel disease, androgenic alopecia, and oncology.

The companys pipeline includes several preclinical programs: ABS-101, ABS-201, ABS-301, and ABS-501, targeting different therapeutic areas. Absci has established strategic partnerships with prominent research institutions and biotech companies, such as Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin, to advance its R&D efforts.

To evaluate Abscis performance, key metrics to consider include its cash runway, R&D expenses as a percentage of revenue, and the progress of its pipeline programs. Given the companys negative P/E ratio and RoE of -53.69, its essential to monitor its burn rate and potential future revenue streams from partnerships or product approvals. Other relevant KPIs include the companys ability to advance its pipeline programs to clinical stages, secure new collaborations, and manage its cash resources effectively.

From a trading perspective, analyzing the stocks trading volume, short interest, and institutional ownership can provide insights into market sentiment. Additionally, tracking news and announcements related to the companys pipeline progress, partnerships, or financial updates can be crucial in understanding the stocks potential price movements.

ABSI Stock Overview

Market Cap in USD 375m
Sub-Industry Biotechnology
IPO / Inception 2021-07-22

ABSI Stock Ratings

Growth Rating -47.9%
Fundamental 23.9%
Dividend Rating -
Return 12m vs S&P 500 -40.9%
Analyst Rating 4.56 of 5

ABSI Dividends

Currently no dividends paid

ABSI Growth Ratios

Growth Correlation 3m -36.6%
Growth Correlation 12m -64%
Growth Correlation 5y -38.6%
CAGR 5y -8.80%
CAGR/Max DD 3y -0.13
CAGR/Mean DD 3y -0.20
Sharpe Ratio 12m -0.81
Alpha 0.22
Beta 0.590
Volatility 104.02%
Current Volume 3026.3k
Average Volume 20d 3129.4k
Stop Loss 2.5 (-7.4%)
Signal 0.81

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-113.3m TTM) > 0 and > 6% of Revenue (6% = 248.3k TTM)
FCFTA -0.35 (>2.0%) and ΔFCFTA -9.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 2564 % (prev 4299 %; Δ -1735 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.36 (>3.0%) and CFO -76.4m > Net Income -113.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 4.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (127.6m) change vs 12m ago 12.98% (target <= -2.0% for YES)
Gross Margin -133.5% (prev -324.5%; Δ 191.1pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 1.78% (prev 1.27%; Δ 0.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -301.4 (EBITDA TTM -100.1m / Interest Expense TTM 374.0k) >= 6 (WARN >= 3)

Altman Z'' -25.02

(A) 0.51 = (Total Current Assets 137.4m - Total Current Liabilities 31.3m) / Total Assets 209.9m
(B) -2.70 = Retained Earnings (Balance) -566.5m / Total Assets 209.9m
warn (B) unusual magnitude: -2.70 — check mapping/units
(C) -0.48 = EBIT TTM -112.7m / Avg Total Assets 232.7m
(D) -15.50 = Book Value of Equity -566.2m / Total Liabilities 36.5m
Total Rating: -25.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 23.86

1. Piotroski 0.50pt = -4.50
2. FCF Yield -28.03% = -5.0
3. FCF Margin data missing
4. Debt/Equity 0.01 = 2.50
5. Debt/Ebitda -0.02 = -2.50
6. ROIC - WACC (= -66.92)% = -12.50
7. RoE -60.21% = -2.50
8. Rev. Trend -45.95% = -3.45
9. EPS Trend 36.10% = 1.80

What is the price of ABSI shares?

As of September 17, 2025, the stock is trading at USD 2.70 with a total of 3,026,261 shares traded.
Over the past week, the price has changed by +6.30%, over one month by -4.59%, over three months by -4.26% and over the past year by -29.87%.

Is Absci a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Absci (NASDAQ:ABSI) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 23.86 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABSI is around 2.28 USD . This means that ABSI is currently overvalued and has a potential downside of -15.56%.

Is ABSI a buy, sell or hold?

Absci has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ABSI.
  • Strong Buy: 5
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ABSI price?

Issuer Target Up/Down from current
Wallstreet Target Price 8.1 201.1%
Analysts Target Price 8.1 201.1%
ValueRay Target Price 2.5 -5.9%

Last update: 2025-09-10 04:30

ABSI Fundamental Data Overview

Market Cap USD = 375.3m (375.3m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 117.5m USD (Cash And Short Term Investments, last quarter)
P/S = 90.6967
P/B = 2.1647
Beta = 2.021
Revenue TTM = 4.14m USD
EBIT TTM = -112.7m USD
EBITDA TTM = -100.1m USD
Long Term Debt = 161.0k USD (from longTermDebt, last quarter)
Short Term Debt = 1.71m USD (from shortTermDebt, last quarter)
Debt = 1.87m USD (Calculated: Short Term 1.71m + Long Term 161.0k)
Net Debt = -30.8m USD (from netDebt column, last quarter)
Enterprise Value = 259.7m USD (375.3m + Debt 1.87m - CCE 117.5m)
Interest Coverage Ratio = -301.4 (Ebit TTM -112.7m / Interest Expense TTM 374.0k)
FCF Yield = -28.03% (FCF TTM -72.8m / Enterprise Value 259.7m)
FCF Margin = -1759 % (FCF TTM -72.8m / Revenue TTM 4.14m)
Net Margin = -2738 % (Net Income TTM -113.3m / Revenue TTM 4.14m)
Gross Margin = -133.5% ((Revenue TTM 4.14m - Cost of Revenue TTM 9.66m) / Revenue TTM)
Tobins Q-Ratio = -0.46 (set to none) (Enterprise Value 259.7m / Book Value Of Equity -566.2m)
Interest Expense / Debt = 2.99% (Interest Expense 56.0k / Debt 1.87m)
Taxrate = 21.0% (US default)
NOPAT = -112.7m (EBIT -112.7m, no tax applied on loss)
Current Ratio = 4.39 (Total Current Assets 137.4m / Total Current Liabilities 31.3m)
Debt / Equity = 0.01 (Debt 1.87m / last Quarter total Stockholder Equity 173.4m)
Debt / EBITDA = -0.02 (Net Debt -30.8m / EBITDA -100.1m)
Debt / FCF = -0.03 (Debt 1.87m / FCF TTM -72.8m)
Total Stockholder Equity = 188.2m (last 4 quarters mean)
RoA = -53.98% (Net Income -113.3m, Total Assets 209.9m )
RoE = -60.21% (Net Income TTM -113.3m / Total Stockholder Equity 188.2m)
RoCE = -59.86% (Ebit -112.7m / (Equity 188.2m + L.T.Debt 161.0k))
RoIC = -58.76% (NOPAT -112.7m / Invested Capital 191.9m)
WACC = 8.16% (E(375.3m)/V(377.2m) * Re(8.19%)) + (D(1.87m)/V(377.2m) * Rd(2.99%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.11%
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -72.8m)
EPS Correlation: 36.10 | EPS CAGR: 11.37% | SUE: -0.42 | # QB: 0
Revenue Correlation: -45.95 | Revenue CAGR: -39.57%

Additional Sources for ABSI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle